Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
J Transl Med. 2023 Feb 27;21(1):155. doi: 10.1186/s12967-023-03909-x.
Breast cancer (BC) is the second most common cancer and cause of death in women. In recent years many studies investigated the association of long non-coding RNAs (lncRNAs), as novel genetic factors, on BC risk, survival, clinical and pathological features. Recent studies also investigated the roles of metformin treatment as the firstline treatment for type 2 diabetes (T2D) played in lncRNAs expression/regulation or BC incidence, outcome, mortality and survival, separately. This comprehensive study aimed to review lncRNAs associated with BC features and identify metformin-regulated lncRNAs and their mechanisms of action on BC or other types of cancers. Finally, metformin affects BC by regulating five BC-associated lncRNAs including GAS5, HOTAIR, MALAT1, and H19, by several molecular mechanisms have been described in this review. In addition, metformin action on other types of cancers by regulating ten lncRNAs including AC006160.1, Loc100506691, lncRNA-AF085935, SNHG7, HULC, UCA1, H19, MALAT1, AFAP1-AS1, AC026904.1 is described.
乳腺癌（BC）是女性中第二常见的癌症和死亡原因。近年来，许多研究调查了长非编码 RNA（lncRNAs）作为新型遗传因素与 BC 风险、生存、临床和病理特征的关联。最近的研究还分别调查了二甲双胍治疗作为 2 型糖尿病（T2D）一线治疗在 lncRNAs 表达/调节或 BC 发病、结局、死亡率和生存率中的作用。这项综合研究旨在综述与 BC 特征相关的 lncRNAs，并确定二甲双胍调节的 lncRNAs 及其在 BC 或其他类型癌症中的作用机制。最后，本综述描述了二甲双胍通过调节五个与 BC 相关的 lncRNAs（包括 GAS5、HOTAIR、MALAT1 和 H19）对 BC 的作用，通过几种分子机制来实现。此外，还描述了二甲双胍通过调节十个 lncRNAs（包括 AC006160.1、Loc100506691、lncRNA-AF085935、SNHG7、HULC、UCA1、H19、MALAT1、AFAP1-AS1 和 AC026904.1）对其他类型癌症的作用。
